170 related articles for article (PubMed ID: 23919277)
21. A high-throughput splicing assay identifies new classes of inhibitors of human and yeast spliceosomes.
Effenberger KA; Perriman RJ; Bray WM; Lokey RS; Ares M; Jurica MS
J Biomol Screen; 2013 Oct; 18(9):1110-20. PubMed ID: 23771823
[TBL] [Abstract][Full Text] [Related]
22. Identification of a small molecule inhibitor that stalls splicing at an early step of spliceosome activation.
Sidarovich A; Will CL; Anokhina MM; Ceballos J; Sievers S; Agafonov DE; Samatov T; Bao P; Kastner B; Urlaub H; Waldmann H; Lührmann R
Elife; 2017 Mar; 6():. PubMed ID: 28300534
[TBL] [Abstract][Full Text] [Related]
23. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.
Jorge J; Petronilho S; Alves R; Coucelo M; Gonçalves AC; Nascimento Costa JM; Sarmento-Ribeiro AB
Invest New Drugs; 2020 Apr; 38(2):369-377. PubMed ID: 31147807
[TBL] [Abstract][Full Text] [Related]
25. The spliceosome inhibitors isoginkgetin and pladienolide B induce ATF3-dependent cell death.
Vanzyl EJ; Sayed H; Blackmore AB; Rick KRC; Fernando P; McKay BC
PLoS One; 2020; 15(12):e0224953. PubMed ID: 33370278
[TBL] [Abstract][Full Text] [Related]
26. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
28. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
29. Modulating splicing with small molecular inhibitors of the spliceosome.
Effenberger KA; Urabe VK; Jurica MS
Wiley Interdiscip Rev RNA; 2017 Mar; 8(2):. PubMed ID: 27440103
[TBL] [Abstract][Full Text] [Related]
30. Total Syntheses of Pladienolide-Derived Spliceosome Modulators.
Sim J; Jang E; Kim HJ; Jeon H
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641481
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs.
Schmittgen TD; Ju JF; Danenberg KD; Danenberg PV
Int J Oncol; 2003 Sep; 23(3):785-9. PubMed ID: 12888918
[TBL] [Abstract][Full Text] [Related]
32. Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.
Arai K; Buonamici S; Chan B; Corson L; Endo A; Gerard B; Hao MH; Karr C; Kira K; Lee L; Liu X; Lowe JT; Luo T; Marcaurelle LA; Mizui Y; Nevalainen M; O'Shea MW; Park ES; Perino SA; Prajapati S; Shan M; Smith PG; Tivitmahaisoon P; Wang JY; Warmuth M; Wu KM; Yu L; Zhang H; Zheng GZ; Keaney GF
Org Lett; 2014 Nov; 16(21):5560-3. PubMed ID: 25376106
[TBL] [Abstract][Full Text] [Related]
33. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
Kim Guisbert KS; Guisbert E
PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
[TBL] [Abstract][Full Text] [Related]
34. Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1.
Pham D; Koide K
Nat Prod Rep; 2016 May; 33(5):637-47. PubMed ID: 26812544
[TBL] [Abstract][Full Text] [Related]
35. Functional analysis of Hsh155/SF3b1 interactions with the U2 snRNA/branch site duplex.
Carrocci TJ; Paulson JC; Hoskins AA
RNA; 2018 Aug; 24(8):1028-1040. PubMed ID: 29752352
[TBL] [Abstract][Full Text] [Related]
36. Chemical Modulation of Pre-mRNA Splicing in Mammalian Systems.
Boer RE; Torrey ZR; Schneekloth JS
ACS Chem Biol; 2020 Apr; 15(4):808-818. PubMed ID: 32191432
[TBL] [Abstract][Full Text] [Related]
37. Synthetic mRNA splicing modulator compounds with in vivo antitumor activity.
Lagisetti C; Pourpak A; Goronga T; Jiang Q; Cui X; Hyle J; Lahti JM; Morris SW; Webb TR
J Med Chem; 2009 Nov; 52(22):6979-90. PubMed ID: 19877647
[TBL] [Abstract][Full Text] [Related]
38. A synthetic entry to pladienolide B and FD-895.
Mandel AL; Jones BD; La Clair JJ; Burkart MD
Bioorg Med Chem Lett; 2007 Sep; 17(18):5159-64. PubMed ID: 17681759
[TBL] [Abstract][Full Text] [Related]
39. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
[TBL] [Abstract][Full Text] [Related]
40. Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.
Hepburn LA; McHugh A; Fernandes K; Boag G; Proby CM; Leigh IM; Saville MK
Oncotarget; 2018 May; 9(33):23029-23046. PubMed ID: 29796170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
